Vaccinex Details Scientific Rationale for Expanding Pepinemab Clinical Programs to Include Alzheimer’s Disease ROCHESTER, N.Y., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...